Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma

Gynecologic Oncology Reports(2025)10.1016/j.gore.2025.101797Source: DataRank Database

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma is a research paper published in Gynecologic Oncology Reports (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.01)OA: goldTopics (20)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Amma Asare ORCID,Jeanne Dockery,Nadia Hameed,Travis T. Sims ORCID,Michael Kim ORCID

Live enrichment

PubMed:40687920 PMC:PMC12271612 OpenAlex:https://openalex.org/W4411644418

National Cancer Institute

The University of Texas MD Anderson Cancer Center

National Institutes of Health

FWCI

2.01

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.gore.2025.101797

publisherhttps://doi.org/10.1016/j.gore.2025.101797

publisherhttps://api.elsevier.com/content/article/PII:S2352578925001225?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352578925001225?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40687920

Fields of Study

Uterine Myomas and TreatmentsEndometrial and Cervical Cancer TreatmentsGestational Trophoblastic Disease Studies

Keywords

MedicineTrastuzumabCarcinosarcomaStage (stratigraphy)Internal medicineOncologyComplete responseCarcinomaCancerChemotherapyBreast cancerHer2Uterine CarcinosarcomaNedTrastuzumab-deruxtecanT-dxdEnhertu

Sustainable Development Goals

SDG 0: Zero hunger

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma

FAIR Checklist

Authors (5)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)